Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700036263

Trial Profile

Clinical Trials Insight: 700036263

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2009

At a glance

  • Drugs CX 1739 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors RespireRx Pharmaceuticals
  • Most Recent Events

    • 28 Jan 2009 Status changed from planning to not yet recruiting, according to a Cortex Pharmaceuticals media release.
    • 15 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top